Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Mirati Therapeutics Inc    MRTX

MIRATI THERAPEUTICS INC

(MRTX)
My previous session
Most popular
  Report  
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
03/19/2019 03/20/2019 03/21/2019 03/22/2019 03/25/2019 Date
73.19(c) 72.77(c) 75.35(c) 73.23(c) 75.43(c) Last
712 066 460 451 475 983 472 926 449 628 Volume
-4.06% -0.57% +3.55% -2.81% +3.00% Change
More quotes
Financials (USD)
Sales 2019 -
EBIT 2019 -143 M
Net income 2019 -138 M
Finance 2019 259 M
Yield 2019 -
Sales 2020 4,04 M
EBIT 2020 -170 M
Net income 2020 -165 M
Finance 2020 76,0 M
Yield 2020 -
P/E ratio 2019 -
P/E ratio 2020
EV / Sales2019 0
EV / Sales2020 620x
Capitalization 2 583 M
More Financials
Company
Mirati Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing a pipeline of targeted oncology products. The Company's clinical pipeline consists of three product candidates: MGCD265, MGCD516 and mocetinostat. MGCD265 and MGCD516 are... 
Sector
Biotechnology & Medical Research
Calendar
05/08 | 01:00amEarnings Release
More about the company
Surperformance© ratings of Mirati Therapeutics Inc
Trading Rating : Investor Rating :
More Ratings
Latest news on MIRATI THERAPEUTICS INC
02/28MIRATI THERAPEUTICS : Management's Discussion and Analysis of Financial Conditio..
AQ
02/28MIRATI THERAPEUTICS, INC. : Results of Operations and Financial Condition, Finan..
AQ
02/21Mirati Therapeutics (MRTX) Reports Faheem Hasnain as New Board Chairman
AQ
02/20MIRATI THERAPEUTICS, INC. : Change in Directors or Principal Officers (form 8-K)
AQ
02/09MIRATI THERAPEUTICS : To Present At The Guggenheim Healthcare Talks Idea Forum &..
AQ
02/08MIRATI THERAPEUTICS : to Present at the Guggenheim Healthcare Talks Idea Forum a..
AQ
01/22MIRATI THERAPEUTICS, INC. : Change in Directors or Principal Officers (form 8-K)
AQ
01/17MIRATI THERAPEUTICS, INC. : Other Events, Financial Statements and Exhibits (for..
AQ
01/16MIRATI THERAPEUTICS, INC. : Results of Operations and Financial Condition (form ..
AQ
2018MIRATI THERAPEUTICS, INC. : Change in Directors or Principal Officers (form 8-K)
AQ
More news
Sector news : Bio Therapeutic Drugs
03/11Regeneron Says FDA Approves Dupixent for Atopic Dermatitis in Adolescents
DJ
03/08Regeneron, Sanofi Get FDA Priority Review for Dupixent
DJ
03/07SHANGHAI RAAS BLOOD PRODUCTS : Spain's Grifols, China's Shanghai RAAS form strat..
RE
03/06GILEAD SCIENCES : Says Once-Daily HIV Regimen Shows Promise in Treating Teens an..
DJ
03/05FDA Approves Controversial Drug for Depression -- Update
DJ
More sector news : Bio Therapeutic Drugs
Chart MIRATI THERAPEUTICS INC
Duration : Period :
Mirati Therapeutics Inc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MIRATI THERAPEUTICS INC
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 13
Average target price 82,0 $
Spread / Average Target 12%
EPS Revisions
Managers
NameTitle
Charles M. Baum President, Chief Executive Officer & Director
Rodney W. Lappe Executive Chairman
Jamie A. Donadio Chief Financial Officer & Senior Vice President
Isan Chen EVP, Chief Medical & Development Officer
James G. Christensen Chief Scientific Officer & Executive VP
Sector and Competitors
1st jan.Capitalization (M$)
MIRATI THERAPEUTICS INC72.63%2 583
GILEAD SCIENCES1.95%81 339
VERTEX PHARMACEUTICALS9.55%46 409
REGENERON PHARMACEUTICALS4.90%42 066
GENMAB8.01%10 747
SAREPTA THERAPEUTICS INC12.03%9 008